Alterity Therapeutics (ATHE) Retained Earnings (2009 - 2025)
Alterity Therapeutics (ATHE) posted quarterly Retained Earnings of -$153.9 million for Q4 2025, down 6.47% year-over-year from -$164.5 million in Q4 2024, and down 6.37% quarter-over-quarter from -$144.7 million in Q2 2025.
Alterity Therapeutics (ATHE) Retained Earnings (2009 - 2025) Analysis & Trends
Alterity Therapeutics' Retained Earnings history runs 17 years deep, the most recent figure standing at -$153.9 million for Q4 2025.
- In Q4 2025, Retained Earnings fell 6.47% year-over-year to -$153.9 million; the TTM figure through Dec 2025 stood at -$153.9 million (down 6.47% YoY), while the FY2025 annual figure was -$144.7 million, down 2.5% from the prior year.
- Retained Earnings for Q4 2025 stood at -$153.9 million, down from -$144.7 million in the prior quarter.
- The five-year high for Retained Earnings was $130.7 million in Q2 2021, with the low at -$153.9 million in Q4 2025.
- The 5-year median for Retained Earnings is -$130.8 million (2022), against an average of -$97.0 million.
- The sharpest annual moves came in 2021 and 2024: Retained Earnings surged 229.14% in 2021, then plunged 7132.96% in 2024.
- Alterity Therapeutics' Retained Earnings stood at -$128.4 million in 2021, then rose by 3.13% to -$124.4 million in 2022, then dropped by 5.49% to -$131.3 million in 2023, then decreased by 10.11% to -$144.5 million in 2024, then decreased by 6.47% to -$153.9 million in 2025.
- Business Quant data shows ATHE's Retained Earnings at -$153.9 million in Q4 2025, -$144.7 million in Q2 2025, and -$144.5 million in Q4 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.57 Bn | 130.72 Bn | 2.84 Bn | 15.69 Bn |
| 2 | Regeneron Pharmaceuticals | 85.98 Bn | 77.99 Bn | 3.93 Bn | 37.62 Bn |
| 3 | Argenx Se | 65.11 Bn | 59.92 Bn | 1.37 Bn | 558.00 Mn |
| 4 | Moderna | 55.73 Bn | 50.59 Bn | 52.00 Mn | 5.10 Bn |
| 5 | BeOne Medicines | 41.99 Bn | 36.89 Bn | 1.53 Bn | 13.05 Bn |
| 6 | Alnylam Pharmaceuticals | 31.64 Bn | 28.33 Bn | 992.69 Mn | -6.33 Bn |
| 7 | BioNTech SE | 27.70 Bn | 9.31 Bn | 668.28 Mn | 20.91 Bn |
| 8 | Insmed | 27.46 Bn | 26.30 Bn | 358.27 Mn | 6.57 Bn |
| 9 | Royalty Pharma | 27.32 Bn | 26.49 Bn | - | 4.38 Bn |
| 10 | Alterity Therapeutics | 48.83 Mn | 16.53 Mn | - | -153.89 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -153.89 Mn |
| Jun 30, 2025 | -144.67 Mn |
| Dec 31, 2024 | -144.53 Mn |
| Jun 30, 2024 | -141.14 Mn |
| Dec 31, 2023 | -131.26 Mn |
| Jun 30, 2023 | -1.95 Mn |
| Dec 31, 2022 | -124.43 Mn |
| Jun 30, 2022 | -130.28 Mn |
| Dec 31, 2021 | -128.44 Mn |
| Jun 30, 2021 | 130.70 Mn |
| Dec 31, 2020 | -119.13 Mn |
| Jun 30, 2020 | -101.21 Mn |
| Dec 31, 2019 | -100.35 Mn |
| Jun 30, 2019 | -98.93 Mn |
| Dec 31, 2018 | -96.35 Mn |
| Jun 30, 2018 | -98.10 Mn |
| Dec 31, 2017 | -97.10 Mn |
| Jun 30, 2017 | -92.13 Mn |
| Dec 31, 2016 | -96.42 Mn |
| Jun 30, 2016 | 93.24 Mn |